MedPath

CLINICAL EVALUATION OF LAVANA BHASKAR CHURN IN AMAJIRNA

Phase 2
Conditions
Health Condition 1: K30- Functional dyspepsia
Registration Number
CTRI/2021/01/030439
Lead Sponsor
Central Council for Research in Ayurvedic Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Closed to Recruitment of Participants
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Patient diagnosed with Amajirna (as per Ayurvedic classics) having the following symptoms/signs

I.ग़�र�ता(Heaviness of whole body/ abdomen),

II.à¤â?°Ã Â¤Â¦Ã Â¥?à¤â??ारशà¥?चयथाभà¥?कà¥?तमविदà¤â??à¥?धà¤Æ?(belching /eructations just after meal),

III.à¤â?°Ã Â¤Â¤Ã Â¥?कà¥?लà¥â?¡Ã Â¤Â¦(Nausea),

IV.à¤â??णà¥?डशà¥â?¹Ã Â¤Â«(Swelling of the cheek),

V.à¤â?¦Ã Â¤•à¥?षिकà¥â??टशà¥â?¹Ã Â¤Â«(Edema of the periorbital region),

VI.स�वाद�वास�यता(sweet taste in mouth)

2.Willing and able to participate for 4 weeks & Subject should be able to provide a written informed consent.

Exclusion Criteria

1.Patients suffering with other type of Ajirna viz. Vishatbdhajirna, Vidagdhajirna, Rasasheshajirna, Dinapakiajirna, Prakrutajirna

2.Subject with Red alarm features (unintentional weight loss, persistent vomiting, dysphagia, hematemesis, melena, fever, or jaundice)

3.Subject with known history of serious gastrointestinal disease (including peptic ulcers, malignancy, esophagealdysmotility, a previous endoscopic or radiological diagnosis of GERD and Barrettââ?¬•s esophagus)

4.Patients with (Known cases of) Hypertension ( > 130/80mmHg).

5.Concomitant serious disease of vital organs such as the liver, kidney, heart or lungs.

6.Women who are pregnant, lactating, or planning to conceive.

7.Patients on prolonged (�6 weeks) medication with corticosteroids, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study.

8.History of hypersensitivity to any of the trial drugs or their ingredients.

9.Patients who are judged by the investigators to be unsuitable to participate in the clinical trial (diagnosed psychotic illnesses, substance dependence or alcoholism)

10.Any other condition which the Investigator thinks may jeopardize the study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath